α受体阻断剂治疗BPH研究进展  

Recent progress on the treatment of BPH with α-adrenoceptor antogonists

作　　者：杨智慧[1] 任雷鸣[1] 杨小平[1] 傅绍萱[1] 李蕴山[1] 

机构地区：[1]河北医科大学药理学教研室,石家庄050017

出　　处：《中国药理学通报》1998年第S1期76-79,共4页Chinese Pharmacological Bulletin

基　　金：河北省博士后基金资助;No 96-118

摘　　要：α受体介导的前列腺尿道平滑肌张力增加是BPH相关性尿道梗阻的动力学因素,α_1受体阻断剂是目前BPH内科治疗的首选药。寻求对泌尿道有高选择性α-(1A)受体阻断剂是今后药物研制的发展方向。a adrenoceptor-mediated increases in smooth muscle tone of the prostate gland and urethra acts as a dynamic factor for BPH-related obstruction of the urethra, a1 adrenoceptor antagonists are considered as the first-line therapy for the patients with BPH. The search for selective a1A a-drenoceptor antogonists with high uroselectivity is strategical for drug discovery research.

关 键 词：良性前列腺增生症 药物治疗 Α受体阻断剂 尿道选择性 

分 类 号：R697.3[医药卫生—泌尿科学]